指南与共识炎症性肠病消化内镜

定义溃疡性结肠炎临床试验中的内镜缓解与应答:一项国际共识

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
指南 / 共识 · Aliment Pharmacol Ther · 2017-01-23

国际炎症性肠病研究组织(IOIBD)发起倡议,先系统综述内镜评分系统的技术要点,再由15名炎症性肠病专家经两轮Delphi投票达成共识:内镜缓解定义为溃疡性结肠炎内镜严重程度指数(UCEIS)为0,内镜应答定义为Mayo内镜评分较基线下降≥1级或UCEIS较基线下降≥2分。

要点

  • 内镜缓解定义为UCEIS为0。
  • 内镜应答定义为Mayo内镜评分下降≥1级或UCEIS下降≥2分。
  • 共识指出多数现有内镜指数未经效验,临床试验中定义随意。

核心结论

  • 这些国际推荐是溃疡性结肠炎内镜结局测量指数的首个共识,应在溃疡性结肠炎临床试验中接受前瞻性检验。

研究设计与样本

  • 国际炎症性肠病研究组织(IOIBD)倡议,先系统综述内镜评分系统技术要点,再由15名炎症性肠病领域专家进行两轮Delphi-style投票达成共识。

主要发现

  • 文献综述显示已提出多种评估溃疡性结肠炎疾病活动的内镜指数,但多数未经效验,临床试验中用于定义内镜应答或缓解的定义多为随意设定。

关键数值与推荐

  • 投票结束时,研究者初步将溃疡性结肠炎内镜严重程度指数(UCEIS)0排序为内镜缓解的定义。
  • 投票结束时,研究者初步将Mayo内镜评分较基线下降≥1级或UCEIS较基线下降≥2分排序为内镜应答的定义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, endpoints for clinical trials have been changing from measuring clinical response to mucosal healing in ulcerative colitis. Endoscopic evaluation is the current gold standard to assess mucosal lesions and has become a major measure of therapeutic efficacy in addition to patients reported outcomes. AIM: To achieve consensus on endoscopic definitions of remission and response for clinical trials in patients with ulcerative colitis. METHODS: In reaching the current international recommendations on an International Organization For the Study of Inflammatory Bowel Disease (IOIBD) initiative, we first performed a systematic review of technical aspects of endoscopic scoring systems. Then, to achieve consensus on endoscopic definitions of remission and response for clinical trials, we conducted a two-round vote using a Delphi-style process among fifteen specialists in the field of inflammatory bowel diseases. RESULTS: The literature review showed that many endoscopic indices have been proposed to evaluate disease activity in ulcerative colitis; most are unvalidated and arbitrary definitions have been used in clinical trials for defining endoscopic response or remission. At the end of the voting process, the investigators ranked initially the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) 0 for the definition of endoscopic remission, and a decrease in Mayo endoscopic score ≥1 grade or a decrease in UCEIS ≥2 points for the definition of endoscopic response in ulcerative colitis. CONCLUSIONS: These international recommendations represent the first consensus on measurement indices for endoscopic outcomes in ulcerative colitis. They should be subject to prospective testing in clinical trials of ulcerative colitis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017. PMID: 28112419. doi:10.1111/apt.13948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。